Tessa Therapeutics Announces Presentation of Autologous and Allogeneic Cell Therapy Data at 2021 ASH Annual Meeting
Presentations to feature clinical data from a Phase II CD30 CAR-T therapy study and a Phase I CD30 CAR-EBVST therapy study targeting lymphomas SINGAPORE, Nov 5 (Bernama-GLOBE NEWSWIRE) –Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that…

